In the discovery and investigation of novel biomarkers, tissue immunohistochemistry (IHC) studies are critical, but how do you translate the technology into the clinical laboratory for patient testing once a biomarker target has been identified?
Frontage Laboratories, Inc.
Advertisement
Articles by Frontage Laboratories, Inc.
March 23rd 2022 at 11 am EST | The use of tissue IHC in the development of novel biomarkers and clinical applications.
Advertisement
Latest Updated Articles
Lightship’s Approach to Accessible, Representative, and Impactful Clinical TrialsPublished: February 13th 2025 | Updated: March 4th 2025
Accelerate Inclusive Enrollment and Delivery with LightshipPublished: February 19th 2025 | Updated: February 26th 2025
- Examining the Impact of Exclusionary Behaviors on Team Dynamics
Published: March 24th 2023 | Updated:
Trials and Tribulations of Electronic Patient Consent: Removing Barriers to eConsent AdoptionPublished: April 28th 2021 | Updated:
Sticking to the Plan: Undue Burden Created by Protocol DeviationsPublished: July 26th 2024 | Updated:
Phase III PERSEUS Trial Data Show Darzalex Faspro Combo Improves Survival in Newly Diagnosed Multiple MyelomaPublished: January 31st 2024 | Updated:
Advertisement
Advertisement
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
